|
|
|
|
||
From Frontiers in Oncology ...The following article was recently published: Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells Marco Tucci*†, Anna Passarelli†, Francesco Mannavola, Claudia Felici, Luigia Stefania Stucci, Mauro Cives and Francesco Silvestris Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy Francesco Silvestris is the Principal Investigator at the Bari location Tilsotolimod is mentioned below in this detailed assessment: Based on the preliminary results achieved by agonist of TLR9 in metastatic melanoma, a phase-3 study (IMO-2125) is ongoing while the experimental arm is exploring the effect of Tilsotolimod in combination with ipilimumab in restoring the immunostimulatory activity, the DC activation, the CD8+ cell proliferation as well as a potential abscopal effect (81). file:///C:/Users/nsbpa/AppData/Local/Packages/Microsoft.MicrosoftEdge_8wekyb3d8bbwe/TempState/Downloads/fonc-09-01148 (1).pdf |
return to message board, top of board |